New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:35 EDTV, GOOG, CELG, NFLX, SCTY, LVS, AAPL, SIRI, TSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL SIRI TSLA V GOOG CELG NFLX SCTY LVS
News For AAPL;SIRI;TSLA;V;GOOG;CELG;NFLX;SCTY;LVS From The Last 14 Days
Check below for free stories on AAPL;SIRI;TSLA;V;GOOG;CELG;NFLX;SCTY;LVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
August 19, 2014
10:13 EDTSCTYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CNOOC (CEO) downgraded to Hold from Buy at Jefferies... Guess (GES) downgraded to Neutral from Overweight at Piper Jaffray... Ingersoll-Rand (IR) downgraded at RW Baird... Lehigh Gas (LGP) downgraded to Neutral from Buy at Ladenburg... Lexicon (LXRX) downgraded to Hold from Buy at Gabelli... Monster Beverage (MNST) downgraded to Neutral from Buy at SunTrust... Nobel Biocare (NBHGY) downgraded to Hold from Buy at Berenberg... Saint Joe Co. (JOE) downgraded to Market Perform from Outperform at Raymond James... SolarCity (SCTY) downgraded at RW Baird.
09:38 EDTAAPL, CELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
09:11 EDTSCTYSolarCity downgraded at RW Baird
Subscribe for More Information
08:27 EDTNFLXNetflix international opportunity larger than most realize, says MKM Partners
Subscribe for More Information
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
06:50 EDTGOOGImages show impending Google music subscription service, Android Police says
Subscribe for More Information
06:32 EDTAAPLMorgan Stanley recommends adding to Apple positions
Subscribe for More Information
06:13 EDTGOOGContinental AG hires Google's Seval Oz to lead new division, WSJ reports
Subscribe for More Information
06:00 EDTSCTYSolarCity downgraded to Neutral from Outperform at RW Baird
05:57 EDTGOOGGoogle to offer accounts to children under 13, WSJ reports
Subscribe for More Information
August 18, 2014
16:00 EDTNFLX, AAPL, TSLAOptions Update; August 18, 2014
Subscribe for More Information
13:12 EDTGOOGMicrosoft getting ready to launch Chromebook challengers, 9to5Google says
Subscribe for More Information
09:35 EDTAAPL, TSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN DG TSLA GILD FB ABX WFC C
08:30 EDTAAPLApple starts production of smartphones with sapphire screens, Guardian says
Subscribe for More Information
08:13 EDTTSLATesla Motors volatility expected to move on CEO warns warranty change
Subscribe for More Information
07:58 EDTNFLXNetflix volatility at low end of historic range
Subscribe for More Information
07:58 EDTAAPLApple December quarter EPS likely to beat by 10%+, says RBC Capital
Subscribe for More Information
06:51 EDTTSLAElectric car production soared in China, Xinhua reports
Subscribe for More Information
06:42 EDTAAPLApple may call 5.5-inch iPhone '6L,' 9to5Mac reports
Apple may call its rumored 5.5-inch iPhone model the "6L," 9to5Mac reports, citing Asia-based rumor site Apple Daily. In this scenario, the 4.7-inch iPhone would be called the iPhone 6. Reference Link
05:23 EDTAAPLInvenSense downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded InvenSense (INVN) to Neutral citing valuation with shares near its $25 price target. Goldman also believes the near-term catalyst of share gains at Apple (AAPL) has passed. InvenSense closed Friday down 1c to $24.99.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use